We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » India Clarifies Clinical Trial Requirements for Biosimilars Sponsors
India Clarifies Clinical Trial Requirements for Biosimilars Sponsors
To provide a more unified approach in evaluating biosimilars, India’s Central Drugs Standard Control Organization is requiring sponsors to conduct equivalence, non-inferiority or comparability Phase 3 clinical trials.